Raymond James & Associates decreased its holdings in Teleflex Incorporated (NYSE:TFX) by 6.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,859 shares of the medical technology company’s stock after selling 3,066 shares during the period. Raymond James & Associates’ holdings in Teleflex were worth $11,412,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also added to or reduced their stakes in the business. BlackRock Inc. increased its stake in Teleflex by 3.4% in the fourth quarter. BlackRock Inc. now owns 4,709,341 shares of the medical technology company’s stock worth $1,171,779,000 after purchasing an additional 156,527 shares during the period. American Century Companies Inc. increased its stake in Teleflex by 24.1% in the fourth quarter. American Century Companies Inc. now owns 1,474,609 shares of the medical technology company’s stock worth $366,912,000 after purchasing an additional 286,700 shares during the period. Geode Capital Management LLC increased its stake in Teleflex by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 398,866 shares of the medical technology company’s stock worth $99,192,000 after purchasing an additional 9,515 shares during the period. Renaissance Technologies LLC increased its stake in Teleflex by 511.6% in the fourth quarter. Renaissance Technologies LLC now owns 195,700 shares of the medical technology company’s stock worth $48,694,000 after purchasing an additional 163,700 shares during the period. Finally, Bamco Inc. NY increased its stake in shares of Teleflex by 38.4% during the fourth quarter. Bamco Inc. NY now owns 189,785 shares of the medical technology company’s stock valued at $47,222,000 after buying an additional 52,645 shares during the period. Institutional investors and hedge funds own 90.75% of the company’s stock.
In related news, VP John Deren sold 1,359 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $255.67, for a total transaction of $347,455.53. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Stephen K. M.D. Klasko sold 200 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $248.96, for a total value of $49,792.00. Following the sale, the director now directly owns 8,080 shares in the company, valued at approximately $2,011,596.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 14,259 shares of company stock worth $3,760,536. 2.39% of the stock is owned by corporate insiders.
TFX stock opened at $252.86 on Friday. The company has a market capitalization of $11,569.10, a price-to-earnings ratio of 30.57, a PEG ratio of 1.90 and a beta of 1.22. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.51 and a current ratio of 2.33. Teleflex Incorporated has a 52 week low of $191.04 and a 52 week high of $288.78.
Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, February 22nd. The medical technology company reported $2.44 earnings per share for the quarter, beating analysts’ consensus estimates of $2.40 by $0.04. Teleflex had a return on equity of 16.46% and a net margin of 7.11%. The company had revenue of $595.10 million for the quarter, compared to the consensus estimate of $601.17 million. During the same quarter last year, the company earned $2.13 earnings per share. The firm’s revenue for the quarter was up 15.8% compared to the same quarter last year. analysts forecast that Teleflex Incorporated will post 9.65 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 15th. Investors of record on Friday, March 2nd were given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 0.54%. The ex-dividend date of this dividend was Thursday, March 1st. Teleflex’s payout ratio is currently 41.59%.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.